Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cibus ( (CBUS) ) just unveiled an announcement.
In 2025, Cibus undertook a significant operational streamlining to concentrate capital and resources on commercializing its weed management traits for rice, including a workforce reduction of about 34 employees approved in July 2025 and completed by year-end, consolidation of core operations in San Diego, and deferral of non-partner-funded non-rice activities. Management estimates its rice herbicide tolerance traits could ultimately generate more than $200 million in annual royalties across initial target markets in Latin America and the United States, while its sustainable ingredients initiatives—particularly a yeast fermentation biofragrance program that began generating nominal payments in 2025—could reach $20–40 million in annual revenue over the long term; combined with cost-cutting measures expected to lower annual net cash usage to about $30 million or less in 2026, these moves aim to bolster financial stability while preserving upside from a broader trait portfolio that Cibus plans to advance opportunistically through partner-funded projects.
The most recent analyst rating on (CBUS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.
Spark’s Take on CBUS Stock
According to Spark, TipRanks’ AI Analyst, CBUS is a Neutral.
The score is held down primarily by weak financial performance—ongoing losses and negative operating/free cash flow with limited runway—despite manageable leverage. Technicals are mixed with modest longer-term support but muted momentum. The earnings call adds upside from commercialization milestones and cost-reduction plans, but near-term revenue and liquidity risks remain significant.
To see Spark’s full report on CBUS stock, click here.
More about Cibus
Cibus, Inc. is an agricultural biotechnology company that uses proprietary gene-editing technologies to develop productivity and sustainability traits for major food crops. The company’s primary business model is licensing these plant traits—such as herbicide tolerance and other yield-enhancing characteristics—to global seed companies in exchange for per-acre royalties, targeting both GMO and non-GMO segments of the estimated $12 billion global seed trait market, with an initial emphasis on rice in Latin America and the United States and additional sustainable ingredient applications such as biofragrances and lauric oils.
Average Trading Volume: 226,193
Technical Sentiment Signal: Sell
Current Market Cap: $93.37M
For detailed information about CBUS stock, go to TipRanks’ Stock Analysis page.